Improvement of the multi-performance biocharacteristics of cordycepin using BiloNiosome-core/chitosan-shell hybrid nanocarriers

Kengkittipat, Warut; Kaewmalun, Somrudee; Khongkow, Mattaka; Iempridee, Tawin; Jantimaporn, Angkana; Bunwatcharaphansakun, Phichaporn; Yostawonkul, Jakarwan; Yata, Teerapong; Phoolcharoen, Waranyoo; Namdee, Katawut

doi:10.1016/j.colsurfb.2020.111369

Cited by 14 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cordycepin was administered in different studies using either oral or intravenous routes [ 116 , 117 ]. In this regard, the bioavailability of orally administered cordycepin can be significantly improved using nanoencapsulation of the drug combined with gastric acid inhibition strategies [ 118 ]. Cordycepin can reportedly efficiently protect BBB integrity by reducing local neuroinflammation, reorganizing tight junctions, and prohibiting the activity of NADPH oxidase (NOX) [ 119 ].…”

Section: Tlrs and Pdmentioning

confidence: 99%

The role of Toll-like receptors and neuroinflammation in Parkinson’s disease

Heidari

Yazdanpanah

Rezaei

2022

J Neuroinflammation

123

View full text Add to dashboard Cite

Background Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder, characterized by motor and non-motor symptoms, significantly affecting patients’ life. Pathologically, PD is associated with the extensive degeneration of dopaminergic neurons in various regions of the central nervous system (CNS), specifically the substantia nigra. This neuronal loss is accompanied by the aggregation of misfolded protein, named α-synuclein. Main text Recent studies detected several clues of neuroinflammation in PD samples using postmortem human PD brains and various PD animal models. Some evidence of neuroinflammation in PD patients included higher levels of proinflammatory cytokines in serum and cerebrospinal fluid (CSF), presence of activated microglia in various brain regions such as substantia nigra, infiltration of peripheral inflammatory cells in affected brain regions, and altered function of cellular immunity like monocytes phagocytosis defects. On the other side, Toll-like receptors (TLRs) are innate immune receptors primarily located on microglia, as well as other immune and non-immune cells, expressing pivotal roles in recognizing exogenous and endogenous stimuli and triggering inflammatory responses. Most studies indicated an increased expression of TLRs in the brain and peripheral blood cells of PD samples. Besides, this upregulation was associated with excessive neuroinflammation followed by neurodegeneration in affected regions. Therefore, evidence proposed that TLR-mediated neuroinflammation might lead to a dopaminergic neural loss in PD patients. In this regard, TLR2, TLR4, and TLR9 have the most prominent roles. Conclusion Although the presence of inflammation in acute phases of PD might have protective effects concerning the clearance of α-synuclein and delaying the disease advancement, the chronic activation of TLRs and neuroinflammation might lead to neurodegeneration, resulting in the disease progression. Therefore, this study aimed to review additional evidence of the contribution of TLRs and neuroinflammation to PD pathogenesis, with the hope that TLRs could serve as novel disease-modifying therapeutic targets in PD patients in the future.

show abstract

Section: Tlrs and Pdmentioning

confidence: 99%

The role of Toll-like receptors and neuroinflammation in Parkinson’s disease

Heidari

Yazdanpanah

Rezaei

2022

J Neuroinflammation

123

View full text Add to dashboard Cite

show abstract

“…The bioavailability of cordycepin in vivo after it administrated intravenously or orally can be significantly improved through the above methods, such as coadministration of an ADA inhibitor‐EHNA (Qi et al, 2023; Tsai et al, 2010) and structural modifications to produce cordycepin derivative N‐octanoyl‐cordycepin (Wei et al, 2009). Regretfully, there is a lack of evidence to indicate that the absorption of cordycepin in vivo is enhanced even though in vitro permeability of cordycepin across the human intestinal barrier was increased by nanoparticles (Kengkittipat et al, 2021) and coadministration of pentostatin (Lee et al, 2019). After oral administration, cordycepin, even at a dose of 80 mg/kg, was not detected in rat blood (Lee et al, 2019), or at a dose of 100 mg/kg, the concentration of it in rat blood is extremely low with the C max of only 0.004 μg/mL (Qi et al, 2023), which consequently result in the lack of its oral bioavailability.…”

Section: Discussionmentioning

confidence: 99%

“…Regretfully, there is a lack of evidence to indicate that the absorption of cordycepin in vivo is enhanced even though in vitro permeability of cordycepin across the human intestinal barrier was increased by nanoparticles (Kengkittipat et al, 2021) and coadministration of pentostatin (Lee et al, 2019). After oral administration, cordycepin, even at a dose of 80 mg/kg, was not detected in rat blood (Lee et al, 2019), or at a dose of 100 mg/kg, the concentration of it in rat blood is extremely low with the C max of only 0.004 μg/mL (Qi et al, 2023), which consequently result in the lack of its oral bioavailability.…”

Section: Discussionmentioning

confidence: 99%

“…Nanoparticles could be applied to improve the oral bioavailability of cordycepin. In a study by Kengkittipat et al (2021), biloniosome‐core/chitosan‐shell hybrid nanocarriers were designed and produced via using a solvent (ethanol) injection method with cordycepin as the biloniosome core and chitosan which is mucoadhesive biopolymer as a coating shell. Bile salts were incorporated into nanocarriers to protect them from degradation in the gastrointestinal tract.…”

Section: Methods For Improving the Bioavailability And Efficacy Of Co...mentioning

confidence: 99%

See 1 more Smart Citation

Cordycepin: A review of strategies to improve the bioavailability and efficacy

Chen

Luo

Jiang

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Cordycepin is a bioactive compound extracted from Cordyceps militaris. As a natural antibiotic, cordycepin has a wide variety of pharmacological effects. Unfortunately, this highly effective natural antibiotic is proved to undergo rapid deamination by adenosine deaminase (ADA) in vivo and, as a consequence, its half‐life is shortened and bioavailability is decreased. Therefore, it is of critical importance to work out ways to slow down the deamination so as to increase its bioavailability and efficacy. This study reviews recent researches on a series of aspects of cordycepin such as the bioactive molecule's pharmacological action, metabolism and transformation as well as the underlying mechanism, pharmacokinetics and, particularly, the methods for reducing the degradation to improve the bioavailability and efficacy. It is drawn that there are three methods that can be applied to improve the bioavailability and efficacy: to co‐administrate an ADA inhibitor and cordycepin, to develop more effective derivatives via structural modification, and to apply new drug delivery systems. The new knowledge can help optimize the application of the highly potent natural antibiotic‐cordycepin and develop novel therapeutic strategies.

show abstract

“…Nanoparticles formed via layered double hydroxides (LDHs) also showed promise for enhancing oral vaccine delivery when coated with a combination of chitosan and alginate . Chitosan is a popular material especially for nanoparticles targeting the GIT, as it is not only mucoadhesive but can also both protect carriers and payloads from acid hydrolysis and improve epithelial permeability by opening tight junctions. , Together, LDHs loaded with bovine serum albumin (BSA) and coated with a pH-triggered sacrificial mucoadhesive chitosan layer significantly increased cellular uptake of BSA compared to both uncoated LDHs and free BSA . The protective effects of chitosan in this system stem from some synergism between chitosan and BSA, where chitosan inhibits the activity of gastric pepsin on BSA, prolonging the time to degradation .…”

Section: Mucosae and Nanoparticle Designmentioning

confidence: 99%

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Watchorn

Clasky

Prakash

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Mucus is a complex viscoelastic gel and acts as a barrier covering much of the soft tissue in the human body. High vascularization and accessibility have motivated drug delivery to various mucosal surfaces; however, these benefits are hindered by the mucus layer. To overcome the mucus barrier, many nanomedicines have been developed, with the goal of improving the efficacy and bioavailability of drug payloads. Two major nanoparticle-based strategies have emerged to facilitate mucosal drug delivery, namely, mucoadhesion and mucopenetration. Generally, mucoadhesive nanoparticles promote interactions with mucus for immobilization and sustained drug release, whereas mucopenetrating nanoparticles diffuse through the mucus and enhance drug uptake. The choice of strategy depends on many factors pertaining to the structural and compositional characteristics of the target mucus and mucosa. While there have been promising results in preclinical studies, mucus−nanoparticle interactions remain poorly understood, thus limiting effective clinical translation. This article reviews nanomedicines designed with mucoadhesive or mucopenetrating properties for mucosal delivery, explores the influence of site-dependent physiological variation among mucosal surfaces on efficacy, transport, and bioavailability, and discusses the techniques and models used to investigate mucus−nanoparticle interactions. The effects of non-homeostatic perturbations on protein corona formation, mucus composition, and nanoparticle performance are discussed in the context of mucosal delivery. The complexity of the mucosal barrier necessitates consideration of the interplay between nanoparticle design, tissue-specific differences in mucus structure and composition, and homeostatic or disease-related changes to the mucus barrier to develop effective nanomedicines for mucosal delivery.

show abstract

Improvement of the multi-performance biocharacteristics of cordycepin using BiloNiosome-core/chitosan-shell hybrid nanocarriers

Cited by 14 publications

References 27 publications

The role of Toll-like receptors and neuroinflammation in Parkinson’s disease

The role of Toll-like receptors and neuroinflammation in Parkinson’s disease

Cordycepin: A review of strategies to improve the bioavailability and efficacy

Untangling Mucosal Drug Delivery: Engineering, Designing, and Testing Nanoparticles to Overcome the Mucus Barrier

Contact Info

Product

Resources

About